LOS ANGELES, Nov 7 (Reuters) - Early results from an ongoing study showed that people with newly diagnosed rheumatoid arthritis were more likely to reach clinical remission with Amgen Inc and Wyeth's ...

SEATTLE, WA – Immunex Corporation (Nasdaq: IMNX) and Wyeth-Ayerst Laboratories, a division of American Home Products (NYSE: AHP) announced today that the U.S. Food and Drug Administration (FDA) has ...

THOUSAND OAKS, Calif. and NEW YORK, May 25, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced new results from multiple studies of ENBREL, further expanding the ...

THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., June 20, 2003 – Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced results of a new study assessing the ...

Combining a new drug with the standard initial treatment for rheumatoid arthritis seems to work better than using either medicine alone, research indicates. About 1 percent of people have rheumatoid ...

COLLEGEVILLE, Pa., and THOUSAND OAKS, Calif. A study has found that when given early in the onset of rheumatoid arthritis in combination with other therapies, Amgen’s drug Enbrel (etanercept) can ...

KENILWORTH, N.J. & SEOUL, South Korea--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd. today announced that pivotal Phase 3 clinical studies of SB4, ...

Please provide your email address to receive an email when new articles are posted on . In patients with rheumatoid arthritis who achieve remission with combination therapy and then withdraw either ...

Please provide your email address to receive an email when new articles are posted on . Methotrexate increases the probability of remission with adalimumab or infliximab by 50% in patients with ...

WILMINGTON, Del., Oct 28 (Reuters) - A British charitable trust filed a patent infringement suit against Wyeth and Amgen on Wednesday over their blockbuster Enbrel drug, one of the world's ...